How does cagrilintide work?

Cagrilintide is a long-acting amylin receptor agonist. Amylin is a separate satiety hormone from GLP-1, so it acts on a different receptor family: hypothalamic and brainstem amylin receptors that promote satiety and delay gastric emptying. Half-life on this site's profile is about 7 days. Molecular weight is about 3,700 daltons. Alone, 706 people at 26 weeks lost 6.0% to 10.8% versus 3.0% on placebo. Combined with semaglutide as CagriSema, a Phase 2 trial in 92 adults with type 2 diabetes found 15.6% at 32 weeks versus 5.1% on semaglutide alone and 8.1% on cagrilintide alone. CagriSema remains investigational. This FAQ does not invent a dose. Full record at /compounds/cagrilintide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.